Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05263037 · ClinicalTrials.gov registry record · NA
EaseVRx-8w+ for the Treatment of Chronic Lower Back Pain
A NA study of Depression and Anxiety, sponsored by AppliedVR.
- Active
- Registry status
- NA
- Development phase
- 1,093
- Enrollment target
- 1
- Study location
NCT05263037: Active NA study of Depression and Anxiety, sponsored by AppliedVR.
NCT05263037 is a NA study of Depression and Anxiety that is active but no longer recruiting, run by AppliedVR. The registered enrollment target is 1,093 participants, above the 785-participant average among 679 other Depression trials with a reported enrollment target (39% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05263037, a NA study of Depression and Anxiety, is active but no longer recruiting, sponsored by AppliedVR.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 1,093 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this randomized controlled trial (RCT) is to assess outcomes for virtual reality therapy (including pain intensity, pain interference, anxiety, depression, physical function, sleep, behavioral skills development, health outcomes and satisfaction) along with healthcare utilization and costs in participants with Chronic Low Back Pain.
Primary Outcome
The BPI pain intensity questionnaire is a validated instrument with good content validity, construct validity, and reliability in participants with chronic pain. The range of scores are from 0-10 with higher values implying greater pain intensity. The BPI pain intensity measure contains a single item related to pain intensity
Conditions Studied
Interventions
- DEVICE Sham VR
- DEVICE EaseVRx
Study Locations (1)
California
- AppliedVR - Van Nuys
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,093 participants |
| Start Date | 2022-01-31 |
| Est. Completion | 2026-06 |
| Phase | NA |
What the registry record for NCT05263037 still lists
NCT05263037 is an interventional study that assigns participants to a tested intervention. Its 1,093 participants enrollment target places it among the larger protocols in the corpus, above the 785-participant average among 679 other Depression trials with a reported enrollment target (39% higher).
The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Sham VR is the first listed.
NCT05263037 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05263037 about?
NCT05263037 is a clinical study titled "EaseVRx-8w+ for the Treatment of Chronic Lower Back Pain". The aim of this randomized controlled trial (RCT) is to assess outcomes for virtual reality therapy (including pain intensity, pain interference, anxiety, depression, physical function, sleep, behavioral skills development, health outcomes and satisfaction) along with healthcare utilization and cost...
What is the current status of trial NCT05263037?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,093 participants. The study started on 2022-01-31. Estimated completion is 2026-06.
What conditions does trial NCT05263037 study?
This clinical trial studies the following conditions: Depression, Anxiety, Chronic Low Back Pain.
What interventions are being tested in trial NCT05263037?
The interventions under investigation include: Sham VR (DEVICE), EaseVRx (DEVICE).
Who is sponsoring clinical trial NCT05263037?
This trial is sponsored by AppliedVR, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05263037 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05263037's enrollment target sits among peer trials
1,093 36th of 679 higher than 644 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
Cold and Heat Investigation to Lower Levels of Depression
RECRUITING · NA
-
Dosing rTMS for Depression Post-SCI
RECRUITING · NA
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
Brief Interventions for Coping with Distress
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03754114 · 1,094 participants · NA
Brain Oxygen Optimization in Severe TBI, Phase 3
- NCT06118983 · 1,094 participants · NA
Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF)
- NCT06585241 · 1,094 participants · Phase 4
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
- NCT07196722 · 1,092 participants · Phase 2
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy